Clinical trials: Dry AMD, open to volunteers
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Dry Age-related Macular Degeneration, Geographic Atrophy
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
This is a Phase IIb randomized, clinical trial designed to assess the safety and efficacy of unilateral implantation of the CPCB-RPE1 implant in subjects with geographic atrophy involving the fovea.
- Trial name
- PATCH-AMD (NCT06557460)
- Testing
- Surgical implantation of the CPCB-RPE1 implant
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Regenerative Patch Technologies, LLC
Age-Related Macular Degeneration
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina - the light-sensitive part at the back of…
- Trial name
- NCT03178149
- Testing
- ASP7317, tacrolimus, trimethoprim-sulfamethoxazole
- Where
- 20 sites in United States
- Volunteers
- 42 people
- Sponsor
- Astellas Institute for Regenerative Medicine
Geographic Atrophy Secondary to Age-related Macular Degeneration
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
This is a non-interventional, observational study to provide insights into the short-term progression of GA secondary to AMD in participants aged ≥55 years.
- Trial name
- Pre-GAIN (NCT07144137)
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 75 people
- Sponsor
- Complement Therapeutics
Geographic Atrophy
An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.
- Trial name
- AiiM OLE (NCT07807969)
- Testing
- Vonaprument
- Where
- 7 sites in United States
- Volunteers
- 605 people
- Sponsor
- Annexon, Inc.
Age-Related (Dry) Macular Degeneration
Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection
The goal of this observational clinical study is to learn if DeepMSI AI detects age-related macular degeneration (AMD) biomarkers with sensitivity and specificity equivalent to experienced clinicians in adults over 40 years old.
- Trial name
- NCT07446582
- Testing
- Retina imaging device (MSI-120) and AI (DeepMSI AI)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- AI-Spectral
Dry Age-Related Macular Degeneration, AMD
Evaluation of an Electric Stimulator for Medical Use by Personal (LRTPM1) for Visual Function in Early to Intermediate Dry Age-Related Macular Degeneration
The goal of this clinical trial is to evaluate the efficacy and safety of an electric stimulator for medical use by personal (LRTPM1) in patients with early to intermediate dry age-related macular degeneration.
- Trial name
- NCT07700147
- Testing
- Transcutaneous Electrical Stimulation
- Where
- 3 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Nu Eyne Co., Ltd.
Dry Age-related Macular Degeneration
Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD
This study is a Phase 3 multicenter, randomized, controlled, assessor blinded, adaptive study in which subjects will be randomized in a 2:1(OCU410: control) ratio to treatment arm or control arm
- Trial name
- NCT07770828
- Testing
- OCU410
- Where
- 3 sites in United States
- Volunteers
- 237 people
- Sponsor
- Ocugen
Dry Age Related Macular Degeneration, Mild Cognitive Impairment (MCI)
Study to Detect Dendritic Cell Recruitment in Human Retina
The goal of this study is to develop an optimal method to detect the immune cells (cells that protect the human body against diseases) in association with abnormal conditions of the retina (light sensitive tissue in the back of…
- Conditions
- Dry Age Related Macular Degeneration, Mild Cognitive Impairment (MCI), Alzheimer Disease
- Trial name
- ICG-002 (NCT06872658)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- MindImmune Therapeutics, Inc.
Dry Age-related Macular Degeneration, Vision Impairment and Blindness
Vision Improvement for Legally Blind Dry AMD Patients
This retrospective observational study is intended to assess the feasibility of using a nonsignificant risk device for vision improvement for legally blind dry AMD patients.
- Trial name
- NCT04875234
- Testing
- Clear-K Low Vision Aid Treatment
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Optimal Acuity Corporation
Age Related Macular Degeneration (AMD)
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been treated in an antecedent study.
- Trial name
- ORACLE (NCT05481827)
- Testing
- GT005
- Where
- 32 sites in United States, Australia and 4 more
- Volunteers
- 225 people
- Sponsor
- Gyroscope Therapeutics Limited
Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD)
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD.
- Conditions
- Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
- Trial name
- i-SIGHT2 (NCT06662162)
- Testing
- i-Lumen AMD
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 100 people
- Sponsor
- i-Lumen Scientific AUS PTY LTD
Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD
This is a Phase 1/2 study, multi-center, dose-escalation interventional study of BS01 in subjects with GA secondary to dry AMD. Part 1 is an open label dose-escalation study; Part 2 is a dose-expansion study with dose(s) selected…
- Trial name
- NCT07158775
- Testing
- BS01
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Bionic Sight LLC
Cataract, AMD - Age-Related Macular Degeneration
Safety and Clinical Performance of the LENTIS® MAX LS-313 MF80 Compared With the Monofocal L-313 in Cataract Patients With Late Age-Related Macular Degeneration: A Multicenter Comparative Clinical Investigation.
The goal of this clinical trial is to evaluate the safety, visual performance, and potential clinical benefits of the LENTIS® MAX LS-313 MF80 intraocular lens compared with the monofocal LENTIS® L-313 intraocular lens in adult…
- Trial name
- NCT07915076
- Testing
- Intraocular Lens
- Volunteers
- 35 people
- Sponsor
- Teleon Surgical B.V.
Epiretinal Membrane, Dry Age Related Macular Degeneration
(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.
- Conditions
- Epiretinal Membrane, Dry Age Related Macular Degeneration, Macular Abnormalities, Retina Disease
- Trial name
- NCT07680244
- Testing
- PathFinder 1.0 on CIRRUS HD-OCT
- Where
- 6 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Carl Zeiss Meditec-Dublin CoCe
Retinal Disease, Macular Degeneration
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD).
- Conditions
- Retinal Disease, Macular Degeneration, Age-Related Macular Degeneration, Geographic Atrophy
- Trial name
- NCT06394232
- Testing
- Eyecyte-RPE™
- Where
- 3 sites in India
- Volunteers
- 54 people
- Sponsor
- Eyestem Research Pvt. Ltd.
Dry Age-related Macular Degeneration
Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)
The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.
- Trial name
- NCT04627428
- Testing
- RPESC-RPE-4W
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Luxa Biotechnology, LLC
Dry AMD, Geographic Atrophy
Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration as Clinical Endpoints
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrialized countries and affects tens of millions of people worldwide, with a rapidly increasing prevalence.
- Conditions
- Dry AMD, Geographic Atrophy, Healhty
- Trial name
- VIRETTA (NCT07433088)
- Testing
- Object recognition and selection task
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Streetlab
Geographic Atrophy
Safety and Efficacy Study of Novel Gene Therapy AGX-08 for Geographic Atrophy
This is AGX-08's safety, tolerability, and efficacy in Geographic Atrophy first-in-human study. This trial is meant to evaluate the safety and efficacy of AGX-08 in Geographic Atrophy patients.
- Trial name
- NCT07602127
- Testing
- AGX-08-L, AGX-08-H, AGX-08-S
- Volunteers
- 24 people
- Sponsor
- Augelux Therapeutics
Dry Age-related Macular Degeneration
A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (GLOBALIGHT)
The purpose of this registry study is to collect real life data pertaining to the safety and clinical effectiveness of multi-wavelength photobiomodulation (PBM) as provided by the Valeda Light Delivery System in participants with…
- Trial name
- NCT06351605
- Testing
- Valeda® Light Delivery System
- Where
- 6 sites in United States, Norway
- Volunteers
- 500 people
- Sponsor
- LumiThera, Inc.